公开(公告)号：WO03068207A2

公开(公告)日：2003-08-21

申请号：PCT/EP0350015

申请日：2003-02-11

Applicant: SOLVAY PHARM BV ,  BRONZOVA JULIANA B ,  FEENSTRA ROELOF W ,  GLENNON JEFFREY C ,  MCCREARY ANDREW C ,  VAN RANDEN JAN ,  RONKEN ERIC ,  VAN SCHARRENBURG GUSTAAF J M

Inventor： BRONZOVA JULIANA B ,  FEENSTRA ROELOF W ,  GLENNON JEFFREY C ,  MCCREARY ANDREW C ,  VAN RANDEN JAN ,  RONKEN ERIC ,  VAN SCHARRENBURG GUSTAAF J M

IPC: A61K45/00 ,  A61K31/00 ,  A61K31/138 ,  A61K31/445 ,  A61K31/48 ,  A61K31/495 ,  A61K31/535 ,  A61K31/55 ,  A61K45/06 ,  A61P25/00 ,  A61P25/14 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P43/00

CPC classification number: A61K31/55 ,  A61K31/00 ,  A61K31/138 ,  A61K31/445 ,  A61K31/48 ,  A61K31/495 ,  A61K31/535

Abstract: The invention relates to the use of a compound or a combination of compounds having partial dopamine-D2 receptor agonistic activity and serotonin and/or noradrenaline reuptake inhibitory activity, for the preparation of a pharmaceutical composition for the treatment of psychiatric and/or neurologic disorders caused by disturbances of the major monoaminergic dopamine, serotonin and/or nordrenaline systems or that can be treated via manipulation of those systems.

Abstract translation: 本发明涉及使用具有部分多巴胺-D2受体激动活性的化合物或组合，以及5-羟色胺和/或去甲肾上腺素再摄取抑制活性，用于制备用于治疗引起的精神病和/或神经障碍的药物组合物 主要的单胺能多巴胺，5-羟色胺和/或肾上腺素系统的紊乱或可以通过操纵这些系统来治疗。

公开(公告)号：WO2007144422A3

公开(公告)日：2008-03-13

申请号：PCT/EP2007055956

申请日：2007-06-15

Applicant: SOLVAY PHARM BV ,  MCCREARY ANDREW C ,  VAN SCHARRENBURG GUSTAAF J M ,  TULP MARTINUS TH M

Inventor： MCCREARY ANDREW C ,  VAN SCHARRENBURG GUSTAAF J M ,  TULP MARTINUS TH M

IPC: A61K45/06 ,  A61K31/195 ,  A61K31/496 ,  A61P25/14 ,  A61P25/16

CPC classification number: A61K31/195 ,  A61K31/496 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention concerns the use of a combination preparation of bifeprunox or its N-oxide, or pharmacologically acceptable salts of those compounds: and L-DOPA, for simultaneous, separate or sequential use in the treatment of disorders requiring recovery of dopaminergic function, in particular Parkinson's disease and restless leg syndrome.

Abstract translation: 本发明涉及双岐杆菌或其N-氧化物或这些化合物的药理学上可接受的盐的组合制剂以及L-DOPA用于同时，分别或顺序地用于治疗需要恢复多巴胺能功能的疾病，特别是 帕金森病和不宁腿综合征。

公开(公告)号：PT1542678E

公开(公告)日：2010-05-25

申请号：PT03797318

申请日：2003-09-17

Applicant: SOLVAY PHARM BV

Inventor： KRUSE CORNELIS G ,  LANGE JOSEPHUS H M ,  MCCREARY ANDREW C ,  STUIVENBERG HERMAN H VAN

IPC: A61K31/41 ,  A61P25/18 ,  C07D235/00 ,  C07D249/10

公开(公告)号：AT458479T

公开(公告)日：2010-03-15

申请号：AT03797318

申请日：2003-09-17

Applicant: SOLVAY PHARM BV

Inventor： LANGE JOSEPHUS H M ,  KRUSE CORNELIS G ,  MCCREARY ANDREW C ,  VAN STUIVENBERG HERMAN H

IPC: A61K31/41 ,  C07D235/00 ,  A61P25/18 ,  C07D249/10

Abstract: The present invention relates to a group of 1H-1,2,4-triazole-3-carboxamide derivatives, to methods for the preparation of these compounds, and to pharmaceutical compositions containing at least one of these compounds as an active ingredient. These 1H-1,2,4-triazole-3-carboxamide derivatives are potent cannabinoid-CB 1 receptor agonists, partial agonists, inverse agonists or antagonists, useful for the treatment of disorders involving cannabinoid neurotransmission. The compounds have the general formula (I) wherein R and R 1 -R 3 have the meanings given in the specification.

公开(公告)号：DE602004022562D1

公开(公告)日：2009-09-24

申请号：DE602004022562

申请日：2004-09-23

Applicant: SOLVAY PHARM BV

Inventor： IWEMA BAKKER WOUTER I ,  VAN SCHARRENBURG GUSTAAF J M ,  VAN DEN HOOGENBAND ADRIANUS ,  MCCREARY ANDREW C

IPC: A61K31/4985 ,  A61P1/08 ,  A61P29/00 ,  C07D471/04

Abstract: The invention relates to hexahydro-pyrido[1,2-a]pyrazine derivatives having interesting neurokinin-NK1 receptor antagonistic activity. The invention also relates to methods for the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these compounds as an active ingredient, as well as to the use of these compositions for the treatment of disorders in which neurokinin receptors are involved. The invention relates to compounds represented by the general formula (1) wherein the symbols have the meanings as given in the description.

公开(公告)号：AU2004275530B8

公开(公告)日：2009-08-20

申请号：AU2004275530

申请日：2004-09-23

Applicant: SOLVAY PHARM BV

Inventor： HOOGENBAND ADRIANUS VAN DEN ,  SCHARRENBURG GUSTAAF J M VAN ,  MCCREARY ANDREW C ,  BAKKER WOUTER I IWEMA

IPC: A61P1/08 ,  A61P29/00 ,  C07D471/04

公开(公告)号：AU2004275530B2

公开(公告)日：2009-07-30

申请号：AU2004275530

申请日：2004-09-23

Applicant: SOLVAY PHARM BV

Inventor： HOOGENBAND ADRIANUS VAN DEN ,  SCHARRENBURG GUSTAAF J M VAN ,  MCCREARY ANDREW C ,  BAKKER WOUTER I IWEMA

IPC: A61P1/08 ,  A61P29/00 ,  C07D471/04

公开(公告)号：ES2317335T3

公开(公告)日：2009-04-16

申请号：ES05816322

申请日：2005-12-06

Applicant: SOLVAY PHARM BV

Inventor： FEENSTRA ROELOF W ,  STOIT AXEL ,  TERPSTRA JAN-WILLEM ,  PRAS-RAVES MARIA L ,  MCCREARY ANDREW C ,  VAN VLIET BERNARD J

IPC: A61K31/423 ,  A61P25/00 ,  C07D263/58

Abstract: Compuestos de fórmula general (1): ** ver fórmula** en donde X= Su O, R1 es H, alquilo(C1-C6), CF3, CH2CF3, OH u O-alquilo(C1-C6), R 2 es H, alquilo(C 1-C 6), halógeno o ciano, R3 es H ó alquilo(C1-C6), R 4 es H, alquilo(C 1-C 6), opcionalmente sustituido con un átomo de halógeno, en donde: ** ver fórmula** se selecciona del grupo que consiste en:** ver fórmula** y los tautómeros, estereoisómeros y N-óxidos de los mismos, así como las sales, hidratos y solvatos farmacológicamente aceptables de dichos compuestos de fórmula (1) y sus tautómeros, estereoisómeros y N-óxidos.

公开(公告)号：PT1919883E

公开(公告)日：2009-03-26

申请号：PT06778284

申请日：2006-08-21

Applicant: SOLVAY PHARM BV

Inventor： FEENSTRA ROELOF W ,  MCCREARY ANDREW C ,  HESSELINK MAYKE B ,  KOOPMAN THEODORUS S M ,  KOSTER HENDRIK J ,  AMSTERDAM PETER H VAN ,  VERHAGE MARINUS ,  SCHARRENBURG GUSTAAF J M VAN

IPC: C07D263/58 ,  A61K31/423 ,  A61P25/00 ,  C07D263/00 ,  C07D295/00 ,  C07D295/24

公开(公告)号：DE602006004363D1

公开(公告)日：2009-01-29

申请号：DE602006004363

申请日：2006-08-21

Applicant: SOLVAY PHARM BV

Inventor： KOOPMAN THEODORUS S ,  KOSTER HENDRIK J ,  VAN AMSTERDAM PETER H ,  FEENSTRA ROELOF W ,  VERHAGE MARINUS ,  MCCREARY ANDREW C ,  HESSELINK MAYKE B ,  VAN SCHARRENBURG GUSTAAF J

IPC: C07D263/58 ,  A61K31/423 ,  A61P25/00 ,  C07D295/24

Abstract: The present invention relates to N-oxides of certain piperazine and piperidine derivatives and to methods for the preparation of these compounds. The invention also relates to the use of compounds disclosed herein for the manufacture of a medicament giving a beneficial effect. A beneficial effect is disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. The invention also relates to the use of a compound of the invention for the manufacture of a medicament for treating or preventing a disease or condition. More particularly, the invention relates to a new use for the treatment of a disease or condition disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. In embodiments of the invention specific compounds disclosed herein are used for the manufacture of a medicament useful in the treatment of CNS-disorders, in particular the treatment of anxiety disorders, including generalized anxiety disorder and panic disorder, obsessive compulsive disorder, aggression, addiction (including craving), depression, autism, vertigo, schizophrenia and other psychotic disorders, Parkinson's disease and disturbances of cognition and memory. The compounds have the general formula (1) wherein the symbols have the meanings given in the specification.